Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
J. C. Janssen, B. van Dijk, K. de Joode, M. J.B. Aarts, F. W.P.J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J.M. van den Eertwegh, J. W.B. de Groot, M. Jalving, M. J.A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A.T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de HoopE. E.A.P. Mulder, Astrid A.M. van der Veldt*
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol'. Together they form a unique fingerprint.